Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

<p dir="ltr">The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibod...

Full description

Saved in:
Bibliographic Details
Main Author: Farah M. Shurrab (16324961) (author)
Other Authors: Duaa W. Al-Sadeq (10976754) (author), Haissam Abou-Saleh (497840) (author), Nader Al-Dewik (4166527) (author), Amira E. Elsharafi (18300841) (author), Fatima M. Hamaydeh (18300844) (author), Bushra Y. Abo Halawa (18300847) (author), Tala M. Jamaleddin (18300850) (author), Huda M. Abdul Hameed (18300853) (author), Parveen B. Nizamuddin (14590613) (author), Fathima Humaira Amanullah (18300856) (author), Hanin I. Daas (17863886) (author), Laith J. Abu-Raddad (9262524) (author), Gheyath K. Nasrallah (9200525) (author)
Published: 2022
Subjects:
Biomedical and clinical sciences
Immunology
Pharmacology and pharmaceutical sciences
neutralizing antibodies
Pfizer-BNT162b2
Moderna-mRNA-1273
SARS-CoV-2
vaccine
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items